Azithromycin Treatment for Campylobacter Infections

Primary Treatment Recommendations

The Journal of Travel Medicine recommends azithromycin as the first-line antibiotic for Campylobacter gastroenteritis, particularly in regions with high fluoroquinolone resistance, with a dosing regimen of either a single 1000 mg oral dose or 500 mg daily for 3 days 1, 2
For adults with Campylobacter infection, a single-dose regimen of 1000 mg orally once is recommended, with an alternative regimen of 500 mg orally daily for 3 days 1, 2
The Centers for Disease Control and Prevention (CDC) recommends alternative dosing for children with Campylobacter enterocolitis: 10 mg/kg on day 1, followed by 5 mg/kg daily for days 2-5 3

The Journal of Travel Medicine recommends empiric use of azithromycin in Southeast Asia and India due to high fluoroquinolone-resistant Campylobacter prevalence exceeding 85% 1
Azithromycin is mandatory as first-line therapy in any geographic area where Campylobacter is suspected clinically 1

The Journal of Travel Medicine recommends treating with azithromycin when dysentery is present (bloody diarrhea with fever) 1, 2
Treatment should be initiated when severe watery diarrhea causing incapacitation is present 1, 2
Early treatment (<72 hours) is particularly effective for campylobacteriosis 1

The Journal of Travel Medicine recommends that azithromycin may be combined with loperamide for faster symptomatic relief, with a dosing regimen of 4 mg initial dose, then 2 mg after each loose stool (maximum 16 mg/24 hours) 1, 2
Loperamide should not be continued if symptoms worsen or dysentery develops 1

The CDC recommends not administering azithromycin simultaneously with aluminum- or magnesium-containing antacids, as it reduces azithromycin absorption 3
Antacids should be spaced at least 2 hours before or after azithromycin 3

The CDC reports that gastrointestinal discomfort occurs in 3-4% of patients taking azithromycin, including nausea, abdominal pain, and diarrhea 3, 2
Azithromycin is significantly better tolerated than fluoroquinolones, which carry risks of tendon rupture, C. difficile, and QT prolongation 2

The CDC recommends monitoring infants <1 month receiving azithromycin for infantile hypertrophic pyloric stenosis (IHPS), though azithromycin has a lower risk than erythromycin 3
Azithromycin is preferred over erythromycin in this age group 3

The Journal of Travel Medicine reports that azithromycin has fewer serious adverse effects compared to fluoroquinolones 2
The CDC recommends azithromycin over erythromycin due to better tolerance and fewer gastrointestinal side effects 3

The Journal of Travel Medicine recommends not delaying treatment beyond 72 hours of symptom onset, as early treatment is particularly effective for campylobacteriosis 1
Rifaximin has a 50% treatment failure rate with invasive pathogens, including Campylobacter, and should be reserved only for non-dysenteric, non-febrile traveler's diarrhea 2, 1